Exsilio Therapeutics Launches with $82 Million to Develop mRNA-Based Genomic Medicines Under Tal Zaks’ Leadership

1. Exsilio Therapeutics Launch: Exsilio Therapeutics has broken cover with $82 million in funding to develop mRNA-based genomic medicines, led by Tal Zaks, former Moderna executive.
2. Tal Zaks' Involvement: Zaks, a medical oncologist and former Moderna executive, is serving as the temporary CEO of Exsilio, drawn by the company's potential to solve significant problems in gene therapy.
3. Genomic Medicines Approach: Exsilio uses naturally occurring, programmable genetic elements to insert new genes into cells through mRNA intermediates, leveraging in-silico modeling and wet lab-based experimentation.
4. Redosing Capability: Exsilio's technology allows for redosing, which sets it apart from other gene editing companies that focus on one-and-done strategies, providing more flexibility and safety.
5. Investors: The series A funding was co-led by Novartis Venture Fund and Delos Capital, with other investors including CRISPR Therapeutics, OrbiMed, Insight Partners, and J.P. Morgan Life Sciences Private Capital.
6. Market Timing: The launch of Exsilio coincides with a favorable market environment, following the approval of gene therapies and the establishment of a regulatory framework by the FDA.
7. Competitive Advantage: Exsilio's technology can provide entire therapeutic genes, rather than just pieces or smaller portions, and uses existing lipid nanoparticle platforms proven to be safe, scalable, and cost-effective.